Physician profile
Logan Dameron
NPI 1083260764
$3,262.56
in general payments reported to CMS, 2019-2025
22 companies · $905 in 2025
The $905 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $773 · 2023: $774 · 2024: $477 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.61 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $386.21 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $374.29 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $353.06 | 2022-2025 | |
| Pfizer INC. | $344.02 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $342.75 | 2024-2025 | Caplyta |
| Abbvie INC. | $342.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $276.10 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $168.28 | 2021-2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $153.73 | 2022-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.81 | 2021 | |
| Evoke Pharma, INC. | $64.32 | 2025 | |
| Dexcom, INC. | $63.68 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $62.39 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.79 | 2023-2024 | Xifaxan |
| Inspire Medical Systems, INC. | $48.38 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $43.01 | 2025 | |
| Lundbeck LLC | $27.37 | 2022 | |
| Astellas Pharma US INC | $24.97 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $19.38 | 2022 | |
| Gilead Sciences, INC. | $18.12 | 2022 | |
| Sanofi Pasteur INC. | $16.44 | 2023 | |
| Exact Sciences Corporation | $15.12 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Dameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.